Actively Recruiting
Betamethasone Phonophoresis Treatment for Adults with Vitiligo Aged 25 to 40 Years
Led by Cairo University · Updated on 2025-12-05
60
Participants Needed
1
Research Sites
1 weeks
Total Duration
AI-Summary
What This Trial Is About
Vitiligo is a skin condition causing white or light patches due to loss or damage of pigment-producing cells called melanocytes. It affects up to 2% of people worldwide, across all skin types and ages. This trial evaluates the use of betamethasone phonophoresis, a method combining the steroid betamethasone with ultrasound to enhance skin absorption, aiming to improve treatment outcomes for vitiligo patients. Participants are divided into two groups. One group receives betamethasone cream followed by ultrasound application after 20 minutes, and the other group receives ultrasound first then betamethasone cream, both three times a week for one month. The ultrasound uses frequencies between 0.7 to 1.1 MHz and intensities up to 3.0 Watts per cm2, with treatment sessions lasting about 5 to 8 minutes. During the study, researchers will monitor participants for three months focusing on vitiligo management. Patients will undergo assessments to track skin pigmentation changes and treatment effects. Throughout the trial, the safety and response to the combined steroid and ultrasound treatment will be observed, with participants expected to maintain follow-up visits during the study period.
CONDITIONS
Brief Title
Betamethasone Phonophoresis For Vitiligo
Research Team
O
Ola Sabry Abd-Elmaksoud Tarabya, MSc
N
Nisreen Afify Abd-Elrasheed, Professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here